---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-049236"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:23:35.891745+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Foghorn Q3 net loss narrows to $15.8M; CFO Humer resigns; cash runway into 2028

## Summary
- CFO Kristian Humer resigns effective Nov 14, 2025 to pursue other opportunity; no disagreement with company.
- Q3 2025 net loss $15.8M vs $19.1M YoY; collaboration revenue $8.2M (vs $7.8M); R&D expenses $20.0M.
- Cash, equivalents, and marketable securities $180.3M as of Sept 30, 2025; provides cash runway into 2028.
- FHD-909 (SMARCA2 inhibitor) Phase 1 trial in SMARCA4-mutated NSCLC enrolling well; combination data with pembrolizumab and KRAS inhibitors.
- Selective CBP degrader IND-ready in 2026; EP300 degrader IND-enabling studies in 2026; ARID1B degrader advancing to in vivo POC in 2026.

## SEC filing metadata
- accession: 0001628280-25-049236
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828025049236/0001628280-25-049236-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828025049236/fhtx-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-049236
- JSON: https://secwatch.observer/filing/0001628280-25-049236.json
- Plain text: https://secwatch.observer/filing/0001628280-25-049236.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.